ArticleBMC infectious diseases2025
Serological and virological characterization of hepatitis B surface antigen-positive patients with or without Helicobacter pylori co-infection at the university of Gondar comprehensive specialized hospital, Northwest Ethiopia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) is a major global public health issue and the most common etiology of chronic liver disease (CLD). The connection between Helicobacter pylori and patients who are HBsAg positive has not been thoroughly explored and has generated considerable scientific and clinical curiosity, although the debate persists.
objectiveThis study aimed to assess serological and virological characteristics of HBsAg + liver disease patients with and without H. pylori infection.
methodsFrom April 1, 2021, to March 30, 2022, a hospital-based cross-sectional study was conducted at the University of Gondar Comprehensive Specialized Hospital on 384 known HBsAg + liver disease patients recruited using a convenience sampling technique. All the 384 HBsAg + patients were tested for fecal H. pylori antigen. For HBeAg, HBeAb, and HBV-DNA analysis, we recruited only 50 subsamples randomly. Serological tests were performed using commercially available enzyme immunoassay Architect System kits. For virological investigations, HBV-DNA was extracted using the Abbott mSample Preparation System DNA, and then HBV viral load was determined by real-time PCR. GraphPad Prism 8.02 and SPSS 25 were used for data analysis, considering a statistically significant P-value of 0.05.
resultsH. pylori co-infection was found in 153 (39.8%) of HBsAg + study participants. The prevalence of HBeAg (5/25) and HBV-DNA (15/25) was higher among the H. pylori co-infected patient group, whereas HBeAb prevalence (11/25) was lower in the co-infected group. The levels of HBeAg (p < 0.04), HBeAb (p < 0.01), and HBV viral load (p < 0.006) were increased in H. pylori co-infected patients than in HBV mono-infected patients.
conclusionsHBeAg and HBV-viral load were higher in H. pylori co-infected HBsAg + patients. These findings suggested that H. pylori has a role in the increment of clinical, serological, and virological parameters in HBsAg + liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.